Trial Profile
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Anastrozole; Letrozole
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- 11 Dec 2020 Results of exploratory analysis assessing correlation between CTC levels with response to pazopanib presented at the 43rd Annual San Antonio Breast Cancer Symposium.
- 11 Jun 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results assessing the clinical benefit (CB) of Pazopanib combined with nonsteroidal aromatase inhibitors (NSAIs) in patients with ABC resistant to NSAIs, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.